Development, Vol 127, Issue 15 3349-3360, Copyright © 2000 by Company of Biologists

JOURNAL ARTICLES

Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin

S Allard, P Adin, L Gouedard, N di Clemente, N Josso, MC Orgebin-Crist, JY Picard and F Xavier
Unite de Recherches sur l'Endocrinologie du Developpement (INSERM), Ecole Normale Superieure, Departement de Biologie, 92120 Montrouge, France.

Regression of the Mullerian duct in the male embryo is one unequivocal effect of anti-Mullerian hormone, a glycoprotein secreted by the Sertoli cells of the testis. This hormone induces ductal epithelial regression through a paracrine mechanism originating in periductal mesenchyme. To probe the mechanisms of action of anti-Mullerian hormone, we have studied the sequence of cellular and molecular events involved in duct regression. Studies were performed in male rat embryos and in transgenic mice overexpressing or lacking anti-Mullerian hormone, both in vivo and in vitro. Anti-Mullerian hormone causes regression of the cranial part of the Mullerian duct whereas it continues to grow caudally. Our work shows that this pattern of regression is correlated with a cranial to caudal gradient of anti-Mullerian hormone receptor protein, followed by a wave of apoptosis spreading along the Mullerian duct as its progresses caudally. Apoptosis is also induced by AMH in female Mullerian duct in vitro. Furthermore, apoptotic indexes are increased in Mullerian epithelium of transgenic mice of both sexes overexpressing the human anti-Mullerian hormone gene, exhibiting a positive correlation with serum hormone concentration. Inversely, apoptosis is reduced in male anti-Mullerian hormone-deficient mice. We also show that apoptosis is a decisive but not sufficient process, and that epitheliomesenchymal transformation is an important event of Mullerian regression. The most striking result of this study is that anti-Mullerian hormone action in peri-Mullerian mesenchyme leads in vivo and in vitro to an accumulation of cytoplasmic beta-catenin. The co-localization of beta-catenin with lymphoid enhancer factor 1 in the nucleus of peri-Mullerian mesenchymal cells, demonstrated in primary culture, suggests that overexpressed beta-catenin in association with lymphoid enhancer factor 1 may alter transcription of target genes and may lead to changes in mesenchymal gene expression and cell fate during Mullerian duct regression. To our knowledge, this is the first report that beta-catenin, known for its role in Wnt signaling, may mediate anti-Mullerian hormone action.

This article has been cited by other articles:

				X. Wu, S. Wan, S. Pujar, M. E. Haskins, D. H. Schlafer, M. M. Lee, and V. N. Meyers-Wallen A Single Base Pair Mutation Encoding a Premature Stop Codon in the MIS Type II Receptor Is Responsible for Canine Persistent Mullerian Duct Syndrome J Androl, January 1, 2009; 30(1): 46 - 56. [Abstract] [Full Text] [PDF]

				G.D. Orvis, S.P. Jamin, K.M. Kwan, Y. Mishina, V.M. Kaartinen, S. Huang, A.B. Roberts, L. Umans, D. Huylebroeck, A. Zwijsen, et al. Functional Redundancy of TGF-beta Family Type I Receptors and Receptor-Smads in Mediating Anti-Mullerian Hormone-Induced Mullerian Duct Regression in the Mouse Biol Reprod, June 1, 2008; 78(6): 994 - 1001. [Abstract] [Full Text] [PDF]

				P. J. O'Shaughnessy, P. J. Baker, A. Monteiro, S. Cassie, S. Bhattacharya, and P. A. Fowler Developmental Changes in Human Fetal Testicular Cell Numbers and Messenger Ribonucleic Acid Levels during the Second Trimester J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4792 - 4801. [Abstract] [Full Text] [PDF]

				J. Klattig, R. Sierig, D. Kruspe, B. Besenbeck, and C. Englert Wilms' Tumor Protein Wt1 Is an Activator of the Anti-Mullerian Hormone Receptor Gene Amhr2 Mol. Cell. Biol., June 15, 2007; 27(12): 4355 - 4364. [Abstract] [Full Text] [PDF]

				T. T. Tran, D. L. Segev, V. Gupta, H. Kawakubo, G. Yeo, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Regulates Androgen-Induced Gene Expression and Growth in Prostate Cancer Cells through a Nuclear Factor-{kappa}B-Dependent Smad-Independent Mechanism Mol. Endocrinol., October 1, 2006; 20(10): 2382 - 2391. [Abstract] [Full Text] [PDF]

				F. Gao, S. Maiti, N. Alam, Z. Zhang, J. M. Deng, R. R. Behringer, C. Lecureuil, F. Guillou, and V. Huff The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis PNAS, August 8, 2006; 103(32): 11987 - 11992. [Abstract] [Full Text] [PDF]

				Y. Zhan, A. Fujino, D. T. MacLaughlin, T. F. Manganaro, P. P. Szotek, N. A. Arango, J. Teixeira, and P. K. Donahoe Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression Development, June 15, 2006; 133(12): 2359 - 2369. [Abstract] [Full Text] [PDF]

				T. Piltonen, L. Morin-Papunen, R. Koivunen, A. Perheentupa, A. Ruokonen, and J. S. Tapanainen Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome Hum. Reprod., July 1, 2005; 20(7): 1820 - 1826. [Abstract] [Full Text] [PDF]

				S. Y. Park and J. L. Jameson Minireview: Transcriptional Regulation of Gonadal Development and Differentiation Endocrinology, March 1, 2005; 146(3): 1035 - 1042. [Abstract] [Full Text] [PDF]

				S. Edlund, S. Y. Lee, S. Grimsby, S. Zhang, P. Aspenstrom, C.-H. Heldin, and M. Landstrom Interaction between Smad7 and {beta}-Catenin: Importance for Transforming Growth Factor {beta}-Induced Apoptosis Mol. Cell. Biol., February 15, 2005; 25(4): 1475 - 1488. [Abstract] [Full Text] [PDF]

				J. Aubin, A. Davy, and P. Soriano In vivo convergence of BMP and MAPK signaling pathways: impact of differential Smad1 phosphorylation on development and homeostasis Genes & Dev., June 15, 2004; 18(12): 1482 - 1494. [Abstract] [Full Text] [PDF]

				A. Salva, M. P. Hardy, X.-f. Wu, C. M. Sottas, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee Mullerian-Inhibiting Substance Inhibits Rat Leydig Cell Regeneration after Ethylene Dimethanesulphonate Ablation Biol Reprod, March 1, 2004; 70(3): 600 - 607. [Abstract] [Full Text] [PDF]

				A. Kobayashi, W. Shawlot, A. Kania, and R. R. Behringer Requirement of Lim1 for female reproductive tract development Development, February 1, 2004; 131(3): 539 - 549. [Abstract] [Full Text] [PDF]

				K. Jeays-Ward, C. Hoyle, J. Brennan, M. Dandonneau, G. Alldus, B. Capel, and A. Swain Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad Development, August 15, 2003; 130(16): 3663 - 3670. [Abstract] [Full Text] [PDF]

				A. Hossain and G. F. Saunders Synergistic Cooperation between the {beta}-Catenin Signaling Pathway and Steroidogenic Factor 1 in the Activation of the Mullerian Inhibiting Substance Type II Receptor J. Biol. Chem., July 11, 2003; 278(29): 26511 - 26516. [Abstract] [Full Text] [PDF]

				L. M. Roberts, J. A. Visser, and H. A. Ingraham Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development Development, March 5, 2003; 129(6): 1487 - 1496. [Abstract] [Full Text] [PDF]

				V. M. Laurich, A. M. Trbovich, F. H. O'Neill, C. P. Houk, P. M. Sluss, A. H. Payne, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance Blocks the Protein Kinase A-Induced Expression of Cytochrome P450 17{alpha}-Hydroxylase/C17-20 Lyase mRNA in a Mouse Leydig Cell Line Independent of cAMP Responsive Element Binding Protein Phosphorylation Endocrinology, September 1, 2002; 143(9): 3351 - 3360. [Abstract] [Full Text] [PDF]

				D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo PNAS, January 1, 2002; (2002) 221599298. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				L. Messika-Zeitoun, L. Gouedard, C. Belville, M. Dutertre, L. Lins, S. Imbeaud, I. A. Hughes, J.-Y. Picard, N. Josso, and N. di Clemente Autosomal Recessive Segregation of a Truncating Mutation of Anti-Mullerian Type II Receptor in a Family Affected by the Persistent Mullerian Duct Syndrome Contrasts with Its Dominant Negative Activity in Vitro J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4390 - 4397. [Abstract] [Full Text] [PDF]

				M. Dutertre, L. Gouedard, F. Xavier, W.-Q. Long, N. di Clemente, J.-Y. Picard, and R. Rey Ovarian Granulosa Cell Tumors Express a Functional Membrane Receptor for Anti-Mullerian Hormone in Transgenic Mice Endocrinology, September 1, 2001; 142(9): 4040 - 4046. [Abstract] [Full Text] [PDF]

				I. A. Hughes Minireview: Sex Differentiation Endocrinology, August 1, 2001; 142(8): 3281 - 3287. [Abstract] [Full Text] [PDF]

				T. R. Clarke, Y. Hoshiya, S. E. Yi, X. Liu, K. M. Lyons, and P. K. Donahoe Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 Expression Mol. Endocrinol., June 1, 2001; 15(6): 946 - 959. [Abstract] [Full Text] [PDF]

				S. Nef and L. F. Parada Hormones in male sexual development Genes & Dev., December 15, 2000; 14(24): 3075 - 3086. [Full Text]

				D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo PNAS, January 8, 2002; 99(1): 239 - 244. [Abstract] [Full Text] [PDF]